Advanced gastric cancer
Conditions
Interventions
Case series:No
Sponsors
Yuebei People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Gastric cancer patients aged 18 to 75 years; 2. Patients with HER-2 negative advanced metastatic gastric cancer diagnosed by pathology and receiving first-line chemotherapy; 3. No obvious active bleeding. 4. Patients with an expected survival period of >= 6 months; 5. The function of major organs is normal, that is, the following standards are met: the blood routine examination standards must be met (no blood transfusion and blood products within 14 days, no correction with G-CSF and other hematopoietic stimulating factors) 6. ECOG PS score 0-1 points 7. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure>140 mmHg, diastolic blood pressure>90 mmHg); 2. Severe cardiovascular disease in the past: myocardial ischemia or myocardial infarction above grade II, and poorly controlled arrhythmia (including QTc interval >=450 ms for men and >=470 ms for women); according to NYHA criteria, grades III to IV Cardiac insufficiency , or those with left ventricular ejection fraction (LVEF) less than 50% indicated by echocardiography; 3. Patients with positive urine protein (urinary protein test 2+ or above, or 24-hour urine protein quantitative> 1.0g), those with weak positive (±) proteinuria should be carefully enrolled; 4. Abnormal coagulation function (INR>1.5, APTT>1.5 ULN), with bleeding tendency; 5. Patients with a history of psychotropic drug abuse and unable to quit or patients with mental disorders; 6. Patients who have been treated with other anti-angiogenic targeted drugs in the past; 7. According to the judgment of the investigator, patients with other concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study; 8. Those with uncontrolled central nervous system transfer; 9. Pregnant or lactating women; 10. The researcher believes that it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral serum vascular endothelial growth factor level;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactZhang Guoping
Yuebei People's Hospital
Outcome results
None listed